These in vitro observations formulated the basis of the randomized trial SEARCH (Sorafenib and Erlotinib, a Randomized Trial Protocol for the Treatment of Patients with Hepatocellular Carcinoma) in which 720 systemic treatment-naïve advanced HCC patients were treated with sorafenib plus either EGFR inhibitor erlotinib (n = 362) or placebo (n = 358) [39]. The gene discussed is EGFR; the disease is hepatocellular carcinoma.